Yishuo Zhu1, Xuan Wang2, Yujie Cui3, Jin Bai4, Junnian Zheng4, Yuechao Fan1
1Department of Neurosurgery, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
2China University of Mining and Technology, Xuzhou, China.
3Medical Insurance Office, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
4Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou, China.
Summary
Purpose: To demonstrate the progression of glioma influenced by Vitamin C (VC) and the potential molecular mechanism.
Methods: The proliferative and migratory rates of U87 and U251 cells induced with 0, 50 and 100 µM VC were examined by CCK-8 and Transwell assay, respectively and the clinical significance of SYNPO2 in glioma patients was analyzed. Relative level of SYNPO2 in VC-induced glioma cells was detected. By intervening SYNPO2, the involvement of SYNPO2 in the anti-cancer role of VC in inhibiting glioma cell phenotypes was finally confirmed.
Results: VC induction attenuated dose-dependently the proliferative and migratory potentials of glioma cells. A low level of SYNPO2 indicated poor prognosis of glioma. Protein and mRNA levels of SYNPO2 were upregulated in glioma cells induced with VC. The inhibitory effects of VC on proliferative and migratory potentials of glioma cells were partially reversed by knockdown of SYNPO2.
Conclusion: VC blocks glioma cells to proliferate and migrate by upregulating SYNPO2.
Key words: glioma, vitamin C, SYNPO2, proliferation, migration.
Full Text: PDF